研究發現新巨噬細胞亞型
作者:
小柯機器人發布時間:2020/9/4 19:59:53
比利時根特大學Charlotte L. Scott課題組近日取得一項新成果。他們揭示骨橋蛋白表達確定了與脂肪肝中與庫普弗細胞(KCs)不同的已募集巨噬細胞亞型。該研究於2020年9月3日發表於《免疫》。
他們證明了代謝相關性脂肪肝疾病(MAFLD)中的KCs降低,被源自骨髓的巨噬細胞替代。募集的巨噬細胞存在於兩個具有不同激活狀態的亞群中,它們要麼與穩態KC相似,要麼與來自肥胖脂肪組織的脂質相關的巨噬細胞(LAM)相似。肝LAMs表達骨橋蛋白(一種針對非酒精性脂肪性肝炎(NASH)患者的生物標誌物),與纖維化的進展有關。與此相吻合的是,在肝臟區域發現的KAM數量減少的LAM表現為Desmin表達增加。
總之,他們的數據突出了巨噬細胞池內相當大的異質性,並表明在MAFLD中需要更特異的巨噬細胞靶向策略。
據悉,MAFLD代表從簡單脂肪變性到NASH的一系列疾病狀態。肝巨噬細胞,特別是KC,被認為通過其活化在MAFLD的發病機理中起重要作用,儘管這些細胞所起的確切作用仍不清楚。
附:英文原文
Title: Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver
Author: Anneleen Remmerie, Liesbet Martens, Tinne Thoné, Angela Castoldi, Ruth Seurinck, Benjamin Pavie, Joris Roels, Bavo Vanneste, Sofie De Prijck, Mathias Vanhockerhout, Mushida Binte Abdul Latib, Lindsey Devisscher, Anne Hoorens, Johnny Bonnardel, Niels Vandamme, Anna Kremer, Peter Borghgraef, Hans Van Vlierberghe, Saskia Lippens, Edward Pearce, Yvan Saeys, Charlotte L. Scott
Issue&Volume: 2020-09-03
Abstract: Metabolic-associated fatty liver disease (MAFLD) represents a spectrum of disease states ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). Hepatic macrophages, specifically Kupffer cells (KCs), are suggested to play important roles in the pathogenesis of MAFLD through their activation, although the exact roles played by these cells remain unclear. Here, we demonstrated that KCs were reduced in MAFLD being replaced by macrophages originating from the bone marrow. Recruited macrophages existed in two subsets with distinct activation states, either closely resembling homeostatic KCs or lipid-associated macrophages (LAMs) from obese adipose tissue. Hepatic LAMs expressed Osteopontin, a biomarker for patients with NASH, linked with the development of fibrosis. Fitting with this, LAMs were found in regions of the liver with reduced numbers of KCs, characterized by increased Desmin expression. Together, our data highlight considerable heterogeneity within the macrophage pool and suggest a need for more specific macrophage targeting strategies in MAFLD.
DOI: 10.1016/j.immuni.2020.08.004
Source: https://www.cell.com/immunity/fulltext/S1074-7613(20)30357-5